Open AccessIncretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Author(s) -
Elliot J. Glotfelty,
Thomas Delgado,
Luis B. TovaryRomo,
Yu Luo,
Barry J. Hoffer,
Lar̀s Olson,
Tobias E. Karlsson,
Mark P. Mattson,
Brandon K. Harvey,
David Tweedie,
Yazhou Li,
Nigel H. Greig
Publication year - 2019
Publication title -
acs pharmacology and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.271
H-Index - 10
ISSN - 2575-9108
DOI - 10.1021/acsptsci.9b00003
Subject(s) - traumatic brain injury , neuroprotection , medicine , incretin , neurotrophic factors , stroke (engine) , intensive care medicine , bioinformatics , neuroscience , diabetes mellitus , type 2 diabetes , psychiatry , psychology , receptor , endocrinology , biology , engineering , mechanical engineering
Traumatic brain injury (TBI) is becoming an increasing public health issue. With an annually estimated 1.7 million TBIs in the United States (U.S) and nearly 70 million worldwide, the injury, isolated or compounded with others, is a major cause of short- and long-term disability and mortality. This, along with no specific treatment, has made exploration of TBI therapies a priority of the health system. Age and sex differences create a spectrum of vulnerability to TBI, with highest prevalence among younger and older populations. Increased public interest in the long-term effects and prevention of TBI have recently reached peaks, with media attention bringing heightened awareness to sport and war related head injuries. Along with short-term issues, TBI can increase the likelihood for development of long-term neurodegenerative disorders. A growing body of literature supports the use of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (Gcg) receptor (R) agonists, along with unimolecular combinations of these therapies, for their potent neurotrophic/neuroprotective activities across a variety of cellular and animal models of chronic neurodegenerative diseases (Alzheimer's and Parkinson's diseases) and acute cerebrovascular disorders (stroke). Mild or moderate TBI shares many of the hallmarks of these conditions; recent work provides evidence that use of these compounds is an effective strategy for its treatment. Safety and efficacy of many incretin-based therapies (GLP-1 and GIP) have been demonstrated in humans for the treatment of type 2 diabetes mellitus (T2DM), making these compounds ideal for rapid evaluation in clinical trials of mild and moderate TBI.